TiumBio’s Post

If you are experiencing challenges of Liquid Biopsy Assay Validation, watch this insightful webinar from Krystyna Nahlik from LGC Clinical Diagnostics who shares her expertise on overcoming the unique challenges faced in the validation process and introduces the recent and upcoming additions to the #Seraseq liquid biopsy portfolio https://lnkd.in/e-QezaX3

Now more than ever, we are reminded how the safety of our ADG126 SAFEbody and its best-in-class profile is translating to better patient outcomes, including clinical response and survival. With a safety profile comparable to pembrolizumab monotherapy, the ADG126 + pembrolizumab doublet is well positioned to become a new cornerstone #IO therapy that can be broadly combined, addressing indications and patient populations beyond the IO agents available today! With its unique mechanism and ability to target CTLA-4 on Tregs in the tumor microenvironment, ADG126 is designed to take #CTLA-4 to a new level. Check out our publications showcasing its 10x higher combination dosing than ipilimumab, and unique ability to dose more frequently @Q3W and repeatedly beyond 4 cycles: https://loom.ly/m_8X16s

As I just recovered from a damned bronchitis 🤧 last week, I am very pleased to tell that Physiogenex will be presenting at the American Thoracic Society conference #ATS2024 for the first time ! Our poster presentation will deal with the amazing work performed by our expert Dr. Estelle Grasset and the Physiogenex team to develop a novel diet-induced obese Bleomycin-Induced Pulmonary Fibrosis Mouse Model, validated with an anti-fibrotic drug (Alk5 inhibitor). This model represents a new alternative for drug efficacy studies, with a more stable and pronounced lung fibrosis. Our model has been further optimized with the expertise of our great histology and image analysis partners Sciempath Labo, Biocellvia and PharmaNest. Congratulations and thank you Virgile Richard, Cindy Serdjebi, Li Chen, Ph.D., DABT and Mathieu Petitjean for the great work delivered ! We look forward to collaborating further with you and our customers targeting lung fibrosis. If you are also developing a therapy for the treatment of pulmonary fibrosis, please stop at our poster on Monday May the 20th or contact us to schedule a discussion: https://lnkd.in/eR8rpD7H Our CRO services now include lung function measurement by plethysmography 👍. We have a 20-year experience in preclinical drug development and a 97.5% customer satisfaction rate over the last 3 years. Our expertise – your success. #fibrosis #lung #imageanalysis #preclinicalresearch

In this month's Science Spotlight, a team from Germany validated the TruSight Oncology 500 ctDNA assay using reference and patient samples, including Seraseq® ctDNA Reference Material v2 AF1% and Seraseq® ctDNA Reference Material v2 AF0.5%. They demonstrated high sensitivity and low variant detection variability of the assay for SNVs, insertions, deletions and fusions down to a VAF of 0.5% in the reference samples, and the VAFs were concordant with previous dPCR results in patient samples. Interestingly, the sensitivity and variability were dependent on the reference material used, with the Seraseq® ctDNA reference materials resulting in much lower variability and better reported sensitivity. Read the full article here to learn more about their findings! https://hubs.ly/Q02plqvh0 #ScienceSpotlight

🔬 Join Corina Dutcus, MD, SVP at Eisai, in a video interview discussing the phase 3 CLEAR study. Explore how lenvatinib + pembrolizumab transform advanced ccRCC treatment. Watch here: [video]https://buff.ly/3u0FV4o Eisai USS ESMO - European Society for Medical Oncologyy

New TSD on treatment switching! NICE's Decision Support Unit has published a new technical support document, written by Helen Bell Gorrod, Keith R Abrams and I. TSD 24 is an update to TSD 16 and is about treatment switching in randomised controlled trials - including trial design, what to adjust for, how, and reporting guidelines. Treatment switching happens in a lot of oncology trials, and sometimes it means that a standard intention-to-treat analysis doesn't address the decision problem we're interested in. NICE has been open to statistical analyses that adjust for treatment switching for a long time, but these won't be accepted if they are not well justified or are badly carried out. One of the big problems is that evidence submissions often don't adequately explain what has been done and why, and to address this TSD 24 offers comprehensive reporting guidelines. Analyses that are well described are much more likely to be accepted by decision-makers! https://lnkd.in/eGecTHvE

First BLA submission by Adaptaimmune to FDA for #TCR-T in advanced #synovial #sarcoma. The submission has been supported by positive data from Cohort 1 of the pivotal trial SPEARHEAD-1. TCR-T are T cells #engineered ex vivo to express tumor-antigen specific T cell receptors (TCRs) that recognise HLA-presented proteins (HLA restriction of TCRs) that may be derived from any cellular compartment unlikely from #CARs that recognise natively folded proteins at the cell surface. This difference has significant implications first of all the ability of TCR-T to aggressively target tumor cells while minimise toxicity towards healthy tissue. TCR-T are #advanced #medicinal #products. https://lnkd.in/dQbmghS4 https://lnkd.in/dX8rcKtH Sarcoma Patient Advocacy Global Network (SPAGN)

On World Cancer Day, we are all reminded of the bravery of our most critical patients and how crucial it is to provide the best healthcare possible for patients everywhere. At Sysmex, we are dedicated to developing innovative analyzers to help clinical labs provide accurate results regardless of the diagnosis. White Precursor Cell (WPC) testing on the XN-20™ hematology module offers automated, next-level analysis of white blood cells, giving highly skilled laboratory scientists sensitive and specific flagging for the crucial identification of abnormal cells. Efficiency can be gained when WPC testing is reflexed using the XN analyzer’s onboard rules or Caresphere™ Workflow Solution (WS). For more information on how Sysmex can help your laboratory help provide diagnostic testing for critical patients, contact your Sysmex Sales Representative or visit https://ow.ly/nYb450QxtNh. *XN analyzers are FDA-cleared to classify and count blood cells. #WorldCancerDay #Sysmex #Hematology #TogetherForABetterHealthcareJourney

Read our latest thinking on RLTs

📣 NEW! Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism. 📣 Rezolute is initiating start-up activities for the study which will be primarily conducted in the U.S. and patient enrollment is planned to commence in the first half of 2025. 🔗⁠ You can find more information about this exciting development at https://lnkd.in/ectU823P ⁠ #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia ⁠